Clinical trial

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

NCT05677334

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Henagliflozin Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention Continuous Subcutaneous Insulin Infusion Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-03-01

PhasePHASE4

Conditions

Type2diabetesunresolved

Interventions

HenagliflozinDRUG

Continuous Subcutaneous Insulin InfusionDEVICE

Sponsors & collaborators

First Affiliated Hospital of Guangxi Medical Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05677334 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.